On October 3, 2025 HanchorBio, a clinical-stage biotechnology company focusing on immune-oncology and dedicated to developing next-generation multi-specific immunotherapies, reported that an abstract detailing preclinical data on HCB301, the company’s novel tri-specific anti-cancer fusion protein, has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 40th Anniversary Annual Meeting (Press release, Hanchor Bio, OCT 3, 2025, View Source [SID1234656428]). The meeting will take place from November 5 to 9, 2025, in National Harbor, Maryland.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Acceptance for a poster presentation at the SITC (Free SITC Whitepaper) Annual Meeting underscores the scientific rigor and innovation behind HCB301’s development. SITC (Free SITC Whitepaper) is the world’s largest annual conference solely dedicated to cancer immunotherapy. Each year, more than 1,300 abstracts are submitted, evaluated according to rigorous selection criteria based on research quality, novelty, and their potential to advance cancer immunotherapy.

Presentation Details

The accepted abstract, titled "A Novel Tri-Specific Fc Fusion Protein Targeting PD-L1, CD47, and TGFβ Remodels the Tumor Microenvironment and Enhance Anti-Tumor Immunity", will be presented on Saturday, November 8, 2025. The presentation will highlight preclinical efficacy and safety data supporting HCB301’s potential as a first-in-class immune-enhancing biologic that targets key mechanisms of tumor immune evasion.

"We are honored to present these compelling preclinical data at SITC (Free SITC Whitepaper) 2025," said Wenwu Zhai, Chief Scientific Officer of HanchorBio. "HCB301 exemplifies the power of our FBDB platform to rationally design multi-specific biologics that restore immune activity and deliver enhanced anti-tumor responses."

About HCB301

HCB301 is a tri-functional IgG4 Fc fusion protein that incorporates:

An anti-PD-L1 antibody,
A high-affinity SIRPα variant to disrupt CD47-mediated "don’t eat me" signaling, and
A TGF-βRII trap domain.
Following successful preclinical development, HCB301 is now in a Phase 1 multi-regional clinical trial in the U.S. and Taiwan to evaluate its safety, tolerability, and anti-tumor activity in patients with advanced solid tumours.

In preclinical studies, HCB301 demonstrated:

Potent blockade of PD-L1 and TGF-β signaling,
Robust phagocytosis of CD47+ tumor cells in vitro with minimal red blood cell binding, suggesting an improved hematologic safety profile compared to CD47-targeting analogs, and
In vivo efficacy comparable to a triple-agent cocktail across multiple xenograft models.
The abstract will also be published in the Journal for ImmunoTherapy of Cancer (JITC) in February 2026 as part of the SITC (Free SITC Whitepaper) 2025 Final Supplement.

On October 3, 2025 Dispatch Bio, a biotech company engineering a universal treatment across solid tumors, leveraging its first-in-class Flare platform, reported two upcoming presentations at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2025 Annual Meeting, taking place in National Harbor, Md., Nov. 5-9, 2025 (Press release, Dispatch Bio, OCT 3, 2025, View Source [SID1234656429]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details are as follows:

Title: DISP-10 is a novel CAR T and tumor-specific virus combination undergoing clinical development that is designed for use as a universal treatment for epithelial tumors
Abstract: 393
Primary Category: Cellular Therapies
Poster Presentation Day: Friday, Nov. 7
Presenter: Lisa Cucolo, Ph.D., Senior Scientist at Dispatch

Title: Combination of a tumor-specific virus and CAR T to specifically and universally target tumors of epithelial origin and overcome challenges of the tumor microenvironment
Abstract: 394
Primary Category: Cellular Therapies
Poster Presentation Day: Saturday, Nov. 8
Presenter: Raymond Liu, Ph.D., Co-Founder and Head of Synthetic Biology at Dispatch

On October 3, 2025 A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies to selectively target tumor cells and protect normal cells, reported the acceptance of four abstracts for presentation during the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) taking place November 5-9, 2025, in National Harbor, Md (Press release, A2 Biotherapeutics, OCT 3, 2025, View Source [SID1234656430]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A2 Bio will present posters detailing early safety and efficacy from the ongoing phase 1/2 EVEREST-2 study and an enrollment update for the ongoing DENALI-1 study. Additional posters will present approaches to boost potency and preserve selectivity of Tmod-based precision cell therapies. The accepted abstracts are available online on the SITC (Free SITC Whitepaper) website.

Poster Presentation Details

Abstract Title

Presenting Author

Abstract Number

Poster Presentation Date

Location

EVEREST-2: a phase 1/2 study of A2B694, a logic‑gated Tmod CAR T therapy to treat solid tumors expressing mesothelin (MSLN) with HLA-A*02 loss of heterozygosity: initial safety and efficacy results

Jeffrey Ward, M.D., Ph.D.

Washington University

535

Friday, Nov. 7

10 am – 7pm ET

Prince George ABC Halls,

Lower-Level Atrium,

Gaylord National Resort and Convention Center

DENALI-1: a seamless phase 1/2 study of A2B395, a logic gated, allogeneic, Tmod CAR T therapy, in patients with EGFR expressing solid tumors with human leukocyte antigen A*02 loss of heterozygosity

Salman Punekar, M.D.

New York University Langone Health, Perlmutter Cancer Center

585

Genetic screens to identify novel functional modules for a NOT gate

Chawita "Jelly" Netirojjanakul, M.Phil., Ph.D.

A2 Biotherapeutics, Inc.

259

An inducible signal 1 mimic overcomes limited access to antigen for solid tumor cell therapy

Charlie Kirsh, B.S.

A2 Biotherapeutics, Inc.

239

About EVEREST-2

EVEREST-2 (NCT06051695) is a seamless Phase 1/2, open-label, nonrandomized study evaluating the safety and efficacy of A2B694, an autologous logic-gated investigational cell therapy developed from the A2 Bio proprietary Tmod platform. The Tmod platform provides selective killing of tumor cells and protection of normal cells via a dual-receptor design consisting of an activator that targets tumor cells and a blocker that protects normal cells. A2B694 consists of an activator that targets mesothelin and a blocker that targets HLA-A*02. HLA-A*02 is lost in tumor cells and present in normal cells in the eligible patient population. The study is recruiting patients with non-small cell lung cancer, pancreatic cancer, ovarian cancer, colorectal cancer, mesothelioma, and other solid tumors that express mesothelin and have lost HLA-A*02 expression. Patients are enrolled through BASECAMP-1 (NCT04981119), a master prescreening study that identifies patients with HLA LOH at any time in the course of their disease via next-generation sequencing. Upon disease progression the participant may screen for enrollment in EVEREST-2.

About DENALI-1

DENALI-1 (NCT06682793) is a seamless Phase 1/2, open-label, nonrandomized study evaluating the safety and efficacy of A2B395, an allogeneic logic-gated Tmod CAR T-cell product in adults with solid tumors that express EGFR and have lost HLA-A*02 expression, including non-small cell lung cancer, head and neck squamous cell carcinoma, triple-negative breast cancer, renal cell carcinoma, colorectal cancer, and other solid tumors. Patients are enrolled through BASECAMP-1 (NCT04981119), a master prescreening study that identifies patients with HLA LOH at any time in the course of their disease via next-generation sequencing. Upon disease progression the participant may screen for enrollment in DENALI-1.

About BASECAMP-1

BASECAMP-1 (NCT04981119) is a prescreening study to identify patients for potential treatment in A2 Bio clinical trials. It is a novel approach to help optimize patient treatment outcomes by enabling patients’ immune cells to be banked in their healthiest state earlier in their course of cancer treatment. Next-generation sequencing is used to identify patients who have lost HLA-A*02, the biomarker of interest for the A2 Bio studies. Patients eligible for autologous therapy undergo leukapheresis to collect, process, and store patient T cells for future Tmod CAR T cell therapy. BASECAMP-1 is currently enrolling patients with non-small cell lung cancer, pancreatic cancer, ovarian cancer, colorectal cancer, mesothelioma, head and neck squamous cell carcinoma, triple-negative breast cancer, renal cell carcinoma, and other solid tumors.

About the Tmod Platform

A2 Bio has pioneered a precision-targeting cellular system – the Tmod platform – that incorporates two receptors, an activator and a blocker, to aim the powerful armaments of immune cells directly at tumors to unequivocally differentiate tumors from normal tissues. The activator recognizes antigens on tumor cells that trigger their destruction, while the blocker recognizes antigens on normal cells that protect them. This novel blocker technology enables precise, personalized, and effective T-cell targeting. The blocker component equips Tmod cells with the capacity to identify tumors as distinct from normal cells.

On October 3, 2025 Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, reported it will present new data for its lead asset EVX-01 at a poster session at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2025 Annual Meeting taking place in National Harbor November 5-9, 2025 (Press release, Evaxion Biotech, OCT 3, 2025, View Source [SID1234656459]). Designed with Evaxion’s AI-Immunology platform, EVX-01 is a personalized cancer vaccine currently being evaluated as a treatment for advanced melanoma (skin cancer).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Evaxion will present new biomarker and immune data stemming from the ongoing phase 2 trial with EVX-01. The two-year clinical efficacy data from the trial will, as earlier announced, be presented in an oral presentation at the ESMO (Free ESMO Whitepaper) 2025 congress on October 17, 2025. Both datasets will add to an already strong data package for EVX-01, which includes convincing one-year interim data from the phase 2 trial.

The phase 2 trial investigates EVX-01 in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA (pembrolizumab) in patients with advanced melanoma (skin cancer). Each patient enrolled in the trial has received a unique vaccine designed and manufactured based on their individual biology. KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

SITC presentation details:

Abstract title: Immune correlates of clinical response following treatment with the personalized cancer vaccine EVX-01 and Pembrolizumab in advanced melanoma patients
Abstract#: 605
Poster#: 605
Session (category): Clinical trials in progress (subcategory: Skin cancers)
Location: Lower Level Atrium – Prince George’s ABC
Date/Time: Friday, November 7, 2025, 5:10–6:35 p.m. ET/23.10-00.35 CET
Presenter: Michail Angelos Pavlidis, Research Associate at Evaxion
About EVX-01

EVX-01 is a personalized peptide-based cancer vaccine intended for first-line treatment of multiple advanced solid cancers. It is Evaxion’s lead clinical asset.

EVX-01 is designed with our AI-Immunology platform and is tailored to target the unique tumor profile and immune characteristics of each patient. It engages the patient’s immune system to fight off cancer by mounting a targeted response against tumors.

In clinical trials, EVX-01 has demonstrated 69% and 67% Overall Response Rates in patients with advanced melanoma. Further, significant correlations between clinical responses and AI-Immunology predictions have been observed, underlining the predictive power of the platform.

On October 3, 2025 Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), reported its abstract has been accepted for oral presentation at the 40th Annual SITC (Free SITC Whitepaper) Meeting being held November 5-9, 2025 in National Harbor, MD (Press release, Akari Therapeutics, OCT 3, 2025, View Source [SID1234656532]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the oral presentation are as follows:

Title: A Novel Splicing-Targeted ADC Payload Drives Immune Activation, Synergy with Checkpoint Inhibitors, and Enhanced Therapeutic Potential beyond Cytotoxicity

Presenter: Satyajit Mitra Ph.D., Executive Director, Head of Oncology at Akari Therapeutics

Abstract No: 951

Session: 302 Beyond Cytotoxic Chemotherapy: the Next Generation of ADCs for Immune Modulation

Date and Time: Sunday, November 9, 2025 at 11:05 AM ET

Location: Gaylord National Resort and Convention Center – Ballroom Level – Potomac Ballroom

Poster Presentation: Friday, November 7, 2025

Location: Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center

For more information about the SITC (Free SITC Whitepaper) Annual Meeting, please visit sitcancer.org.